u/marta_trevino

Agreed. Reporting by lane rather than by supplier is what made the tables here actually predictive.

glycaemic control and weight are two different endpoints

the tendon claims are the most repeated and the least evidenced

rigid outer packaging is the cheapest quality signal there is

Disagreeing with this bit: a single slow shipment does not move a lane, it joins the distribution.

Careful — the supplier does not control the last mile and most of your variance is in it.

Push back: "no reported harms" in a literature with almost no human trials is not a safety finding.

the food noise going quiet is the effect people actually describe

Disagree with loosening that. The evidence rule is why a supplier report here means something.

Not convinced by four data points. That is not a lane yet, it is an anecdote with a route attached.

stability in solution is the practical question nobody asks

Incretin-based agents stimulate insulin secretion in a glucose-dependent manner, which is why hypoglycaemia risk with them alone is low. Risk rises with agents that act independently of glycaemia.

Strongly agree on protein. It did more for my injection-site soreness than any of the things I bought to fix my injection-site soreness.

It is a fifteen-residue peptide with a published sequence, which makes synthesis straightforward and makes identity verification the meaningful test rather than an optional extra.

Disagree. 2.4 is the top of the label, not the goal, and "everyone ends up there" is just survivorship in the posts you read.

Steady state after a dose change takes four to five half-lives, so the fair judgement point on a new step is about a month, not four days.

Are you measuring anything other than weight? Waist is usually the one that keeps moving.